Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft‐versus‐host disease by inhibiting T‐cell migration to the gastrointestinal tract

Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft‐versus‐host disease by inhibiting T‐cell migration to the gastrointestinal tract

Abstract Introduction Allogeneic hematopoietic stem cell transplantation (aHSCT) is a curative treatment for hematopoietic malignancies. Graft‐versus‐host disease (GVHD) is a major complication of aHSCT. After transplantation, the balance of immune conditions, such as proinflammatory cytokine level...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Yukie Tsubokura, Hideaki Yoshimura, Atsushi Satake, Yutaro Nasa, Ryohei Tsuji, Tomoki Ito, Shosaku Nomura
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: Wiley 2022-09-01
Loạt:Immunity, Inflammation and Disease
Những chủ đề:
graft‐versus‐host disease
hematopoietic stem cell transplantation
lenalidomide
regulatory T cells
Truy cập trực tuyến:https://doi.org/10.1002/iid3.688

Internet

https://doi.org/10.1002/iid3.688

Những quyển sách tương tự